

Pharmacist-Prescribed Paxlovid Guide

The purpose of this document is to serve as a guide for pharmacist prescribed paxlovid based on the paxlovid FDA EUA. Refer to FDA materials for the most up-to-date information for counseling points and the most comprehensive information.

Pg. 1-3: Pathway Pg. 4: Checklist for individual patient Pgs. 5-8: Drug interactions Pg. 8: Resources

A special thanks to CPESN Pharmacies, Eric's Rx Shoppe and Moose Pharmacy, in PA and NC, respectively, for their contributions to this guide.

Pharmacist-Prescribed Paxlovid Assessment and Treatment Care Pathway

Part 1. Review Medical History

Age	Age ≥18 years OR >12 years of age and weighing at least	< 18 years/old OR > 12 and
ASC	40kg (88 lb)	weighs less than 40 kg, STOP
	Continue to next step.	Weights less than 40 kg, STOP
Positive COVID-19	If patient has a positive rapid antigen test or a	If patient has tested positive >
Test	positive PCR test in the last 5 days	5
Test	Continue to next step.	days ago, STOP and consider
	continue to next step.	referring patient for other
		therapy. Therapeutics Locator:
		Click here.
Evaluate Patient's	If nations has mild to moderate symptoms that	If patient started experiencing
	If patient has mild-to-moderate symptoms that started in the last 5 days	
Symptoms	Continue to next step.	symptoms over 5 days ago, STOP
Document date of		
	If patient is experiencing any of the following symptoms, <u>ST</u>	<u>OP</u> and rejer them to emergency
symptom onset	department:	tract
	 Shortness of breath or difficulty breathing +/- while a Increasing severity of cough +/- low oxygen levels 	l Test
	□ Chest or upper abdominal pain/pressure	
	□ Sudden dizziness, weakness or fainting	
	□ Sudden dizziness, weakness of junting □ Sudden change in vision	
	□ Confusion, sudden change in your mental status, diffi	cultu speaking
	□ Sudden or severe pain	curry speaking
	Severe vomiting or diarrhea	
	□ Vomiting or coughing blood	
	 Extreme sleepiness or inability to wake 	
	□ Blue face or lips	
High-Risk Criteria	If patient meets any of the following, continue to next step:	If patient is not high-risk for
	Age over 50, with risk increasing substantially risk	progressing to moderate-to-
For a full list of	\geq 65 years old	severe
risk factors that	Being unvaccinated or not being up to date on	COVID-19 illness, STOP
qualify, click <u>here</u> .	COVID-19 vaccinations	
	Race or ethnicity other than non-Hispanic white	
	individual	
	$\square BMI \ge 25 \text{ kg/m}^2$	
	Asthma or chronic lung disease (e.g., COPD)	
	Cancer	
	Diabetes	
	 Heart conditions HIV 	
	 HIV Sickle cell disease 	
	 Sickle cell disease Pregnancy or recent pregnancy 	
	 Primary immunodeficiency or use of 	
	immunosuppressant	
	Smoking, current or former	
	Liver Disease**	
	☐ Kidney Disease**	
	□ Other:	
**Extra caution warr		

**Extra caution warranted.



Part 2. Obtain Pertinent Lab Values from the Last 12 months

• Ask patient if they have access to provider portal or recent labs. Reach out to provider's office for kidney function, along with updated list of medications if needed.

Renal Function eGFR	If patient's eGFR is > 60 mL/min, continue to next step.	If patient's eGFR is 30-59 mL/min, requires dose	If patient's eGFR is < 30, STOP
		adjustment and continue to next step.	
Hepatic Function	Utilize <u>https://www.mdcalc.com/calc/340/child-pugh-score-cirrhosis-mortality</u> to calculate the patient's Child-Pugh score.		
	If Child-Pugh Score is A or B, continue to next step.	If there are no lab values within the last 12 months to use in the calculator, you may call the patient's PCP to get an assessment of the patient's hepatic function.	If Child-Pugh Score is C, STOP. Consider referring patient to PCP or other local provider who can provide alternative treatments (e.g., MAB)
Review Hypersensitivity Reactions	No history of clinically significant hypersensitivity reactions [e.g., toxic epidermal necrolysis (TEN) or Stevens- Johnson syndrome] to the active ingredients (nirmatrelvir or ritonavir) or other components of the product. Continue to next step.	MAB) Has a present history of clinically significant hypersensitivity reactions [e.g., toxic epidermal necrolysis (TEN) or Stevens-Johnson syndrome] to the active ingredients (nirmatrelvir or ritonavir) or other components of the product. STOP	

Part 3. Obtain Complete Medication List from Patient or Primary Care Provider (or primary pharmacy)

• Ensure a thorough and complete medication list is obtained, including all prescription, OTC, and herbal supplements.

Medication Review COVID-19 Drug Interaction Resource: Click <u>here</u> .	If the patient is NOT taking any of the medications below or those listed on pages 5-8 and all other medications have been checked for interactions and contraindications*, continue to next step. *All medications should be reviewed for possible interactions as this is a guide and not comprehensive	If the patient is taking any medications that causes a possible interaction, call the prescriber / PCP to determine if dose modification is needed for other medication and make referral to authorized non-pharmacist prescriber. If dose modification is not needed, may continue to next step.	If other medication requires dose modification, STOP Refer patient for clinical evaluation (e.g., telehealth, in-person visit) with a physician, APRN, or PA to prescribe drugs, if modification of other medications is needed due to a potential drug interaction.	
	The following medications are contraindicated when taking Paxlovid: alfuzosin, amiodarone, apalutamide, carbamazepine, clozapine, colchicine, dihydroergotamine, dronedarone, eletriptar eplerenone, ergotamine, finerenone, flecainide, flibanserin, ivabradine, lomitapide, lovastatin, lumacaftor/ivacaftor, lurasidone, methylergonovine, midazolam (oral), naloxegol, pethidine, phenobarbital, phenytoin, pimozide, piroxicam, primidone, propafenone, quinidine, ranolazine, rifampin, sildenafil (Revatio [®]) – when used for pulmonary arterial hypertension, silodosin, simvastatin, St. John's Wort, tolvaptan, triazolam, ubrogepant, voclosporin.			



Part 4: Determine appropriate paxlovid dosing based on clinical information obtained.

Choose the	Nirmatrelvir 300 mg/ritonavir 100 mg (3 tablets)	*if eGFR is 30-59, nirmatrelvir 150 mg/
appropriate dose	twice daily for 5 days	ritonavir 100 mg (2 tablets) twice daily
		for 5 days

Part 5: Scan all documents into pharmacy system for future reference.

Part 6: Once criteria is met, make sure patient receives their prescription within a timely manner (offer delivery or curbside pickup).

• Consider offering delivery or curbside pickup

The state-licensed pharmacist should refer an individual patient for clinical evaluation (e.g., telehealth, in-person visit) with a physician, advanced practice registered nurse, or physician assistant licensed or authorized under state law to prescribe drugs, if any of the following apply:

- □ Sufficient information is not available to assess renal and hepatic function.
- □ Sufficient information is not available to assess for a potential drug interaction.
- □ Modification of other medications is needed due to a potential drug interaction.

PAXLOVID is not an appropriate therapeutic option based on the authorized <u>Fact Sheet for Healthcare</u>
 <u>Providers</u> or due to potential drug interactions for which recommended monitoring would not be feasible.



Checklist for Pharmacist-Prescribing for Paxlovid

Patient Name:	Date of Birth:			
Weight:	Date of Assessment:			
Positive Test DocumentedSymptoms started in the last 5	avs			
 Date of Symptoms: Meets high-risk criteria Age over 50, with risk increasing substantially risk ≥ 65 years old Being unvaccinated or not being up to date on COVID-19 vaccinations Race or ethnicity other than non-Hispanic white individual 				
 □ BMI ≥ 25 kg/m² □ Asthma or chronic lung □ Cancer □ Diabetes 	disease (e.g., COPD)			
Heart conditionsHIVSickle cell disease	 Nirmatrelvir 300 mg/ritonavir 100 mg Take 3 tablets PO BID for 5 days #30 			
 Pregnancy or recent pr Primary immunodeficie Smoking, current or for Liver Disease**(extra c Kidney Disease** (extra Other:	Incy or use of immunosuppressantImmatrelvir 150 mg/ritonavir 100 mgInter(Renal Dose Adjustment)Inution)Take 2 tablets PO BID for 5 daysInution)#20			
No history of clinically significant	Pharmacist:			
No known or suspected severe	enal impairment. eGFR > 60 mL/min or eGFR is 30-59 mL/min			
o If eGFR is 30-59 mL/min	, nirmatrelvir 150 mg/ritonavir 100 mg (2 tablets) twice daily for 5 days			
No known or suspected severe	nepatic impairment. Hepatic Function is classified as Child-Pugh Score of A or B			
Access to labs that are within the second	e last 12 months (patient access to provider portal, printed labs, obtained by			
PCP/provider)				
Access to current and complete	medication list.			
Complete Medication List Revie	wed for interactions. No modifications to current drugs needed.			
□ All information received, reviewed, and best course of action decided for the patient.				
Scan all documents (positive te	t, kidney function, other medications) into your pharmacy system under the			
prescription for future reference	<u>ه.</u>			


□ Produce prescription and dispense paxlovid with appropriate dosage.



PAXLOVID Patient Eligibility Screening Checklist Tool for Prescribers

Other Drugs with Established and Other Potentially Significant Drug Interactions with PAXLOVID (listed alphabetically by generic name)

Interaction Codes:



Coadministration of this drug with PAXLOVID is CONTRAINDICATED. For further information, refer to the Fact Sheet for Healthcare Providers and the individual Prescribing Information for the drug.

Coadministration of this drug with PAXLOVID should be avoided and/or holding of this drug, dose adjustment of this drug, or special monitoring is necessary. Consultation with the prescriber of the potentially interacting drug is recommended. For further information, refer to the Health Care Provider Fact Sheet and the individual Prescribing Information for the drug.

The table below provides a listing of clinically significant drug interactions, including contraindicated drugs, <u>in addition to those listed under Concomitant Medications above</u> (HMG-CoA reductase inhibitors [statins], hormonal contraceptives containing ethinyl estradiol, and medications for HIV-1 treatment). **Drugs listed in this table are a guide and are not considered a comprehensive list of all possible drugs that may interact with PAXLOVID.** The healthcare provider should consult other appropriate resources such as the prescribing information for the interacting drug for comprehensive information on dosing or monitoring with concomitant use of a strong CYP3A inhibitor such as ritonavir.

Drug	Drug Class	Interaction Code	
abemaciclib	Anticancer drug	*	***
alfuzosin	Alpha 1-adrenoreceptor antagonist	XXX	
aliskiren	Cardiovascular agent	*	***
amiodarone	Antiarrhythmic	XXX	
amlodipine	Calcium channel blocker	*	***
apalutamide	Anticancer drug	XXX	
avanafil	PDE5 inhibitor	*	***
bedaquiline	Antimycobacterial	*	***
betamethasone	Systemic corticosteroid	*	***
bosentan	Endothelin receptor antagonist	*	***
budesonide	Systemic corticosteroid	*	***
bupropion	Antidepressant	*	***
carbamazepine	Anticonvulsant	XXX	
ceritinib	Anticancer drug	*	***

Drug	Drug Class	Interact Code	ion
ciclesonide	Systemic corticosteroid		***
clarithromycin	Anti-infective		***
clopidogrel	Cardiovascular agent		***
clozapine	Antipsychotic	XXX	
colchicine	Anti-gout	XXX	
cyclosporine	Immunosuppressant		***
dabigatran	Anticoagulants		***
dasabuvir	Hepatitis C direct acting antiviral		***
dasatinib	Anticancer drug		***
dexamethasone	Systemic corticosteroid		***
digoxin	Cardiac glycoside		***
dihydroergotamine	Ergot derivative	XXX	
diltiazem	Calcium channel blocker		***
dronedarone	Antiarrhythmic	XXX	
elbasvir/grazoprevir	Hepatitis C direct acting antiviral		***
eletriptan	Migraine medication	XXX	
elexacaftor/tezacaftor/ivacaftor	Cystic fibrosis transmembrane		***
	conductance regulator potentiator		
encorafenib	Anticancer drug		***
eplerenone	Cardiovascular agent	XXX	
ergotamine	Ergot derivative	XXX	
erythromycin	Anti-infective		***
everolimus	Immunosuppressant		***
felodipine	Calcium channel blocker		***
fentanyl	Narcotic analgesic		***
finerenone	Mineralocorticoid receptor	XXX	
	antagonist		
flecainide	Antiarrhythmic	XXX	
fluticasone	Systemic corticosteroid		***
flibanserin	Serotonin receptor 1A agonist/	XXX	
	serotonin receptor 2A antagonist		
glecaprevir/pibrentasvir	Hepatitis C direct acting antiviral		***
hydrocodone	Narcotic analgesic		***
ibrutinib	Anticancer drug		***
isavuconazonium sulfate	Antifungal		***
itraconazole	Antifungal		***
ivabradine	Cardiovascular agent	XXX	
ivacaftor	Cystic fibrosis transmembrane		***
	conductance regulator potentiator		
ivosidenib	Anticancer drug		***
ketoconazole	Antifungal		***

Drug	Drug Class	Interact Code	ion
lidocaine (systemic)	Antiarrhythmic		***
lomitapide	Microsomal triglyceride transfer	XXX	
	protein (MTTP) inhibitor		
lumacaftor/ivacaftor	Cystic fibrosis transmembrane	XXX	
	conductance regulator potentiator		
lurasidone	Antipsychotic	XXX	
methadone	Narcotic analgesic		***
methylergonovine	Ergot derivative	XXX	
methylprednisolone	Systemic corticosteroid		***
midazolam (administered parentally)	Sedative/hypnotic		***
midazolam (oral)	Sedative/hypnotic	XXX	
mometasone	Systemic corticosteroid		***
naloxegol	Opioid antagonist	XXX	
neratinib	Anticancer drug		***
nicardipine	Calcium channel blocker		***
nifedipine	Calcium channel blocker		***
nilotinib	Anticancer drug		***
ombitasvir/paritaprevir /ritonavir	Hepatitis C direct acting antiviral		***
oxycodone	Narcotic analgesic		***
pethidine	Analgesic	XXX	
phenobarbital	Anticonvulsant	XXX	
phenytoin	Anticonvulsant	XXX	
pimozide	Antipsychotic	XXX	
primidone	Anticonvulsant	XXX	
propafenone	Antiarrhythmic	XXX	
quetiapine	Antipsychotic		***
quinidine	Antiarrhythmic	XXX	
ranolazine	Antianginal	XXX	
rifabutin	Antimycobacterial		***
rifampin	Antimycobacterial	XXX	
rifapentine	Antimycobacterial		***
rimegepant	Migraine medication		***
rivaroxaban	Anticoagulant		***
salmeterol	Long-acting beta-adrenoceptor		***
	agonist		
Sildenafil (when used for erectile	PDE5 inhibitor		***
dysfunction)			
sildenafil (Revatio [®]) when used for	PDE5 inhibitor	XXX	
pulmonary arterial hypertension			
silodosin	Benign prostatic hyperplasia agent	XXX	
sirolimus	Immunosuppressant		***

Drug	Drug Class	Interaction Code	
sofosbuvir/velpatasvir/ voxilaprevir	Hepatitis C direct acting antiviral	***	
St. John's Wort (hypericum perforatum)	Herbal product	XXX	
suvorexant	Neuropsychiatric agent	***	
tacrolimus	Immunosuppressant	***	
tadalafil	PDE5 inhibitor	***	
tamsulosin	Alpha 1-adrenoreceptor	***	
	antagonist		
tezacaftor/ivacaftor	Cystic fibrosis transmembrane	***	
	conductance regulator potentiator		
ticagrelor	Cardiovascular agent	***	
tolvaptan	Vasopressin receptor antagonist	XXX	
trazodone	Antidepressant	***	
triamcinolone	Systemic corticosteroid	***	
triazolam	Sedative/hypnotic	XXX	
ubrogepant	Migraine medication	XXX	
vardenafil	PDE5 inhibitor	***	
venetoclax	Anticancer drug	***	
vinblastine	Anticancer drug	***	
vincristine	Anticancer drug	***	
voclosporin	Immunosuppressant	XXX	
vorapaxar	Cardiovascular agent	***	
voriconazole	Antifungal	***	
warfarin	Anticoagulant	***	

Resources:

- PAXLOVID Fact Sheet for Healthcare Providers: <u>https://www.fda.gov/media/155050/download</u>
- Paxlovid Patient Eligibility Screening Checklist for Prescribers (non-pharmacist): <u>https://www.fda.gov/media/158165/download</u>
- CDC Underlying Medical Conditions: <u>https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html</u>
- University of Liverpool COVID-19 Drug Interactions: <u>https://www.covid19-druginteractions.org/checker</u>
- NIH COVID-19 Treatment Guidelines: <u>https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ritonavir-boosted-nirmatrelvir--paxlovid-/</u>